Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU international Fernández, M. I., Williams, S. B., Willis, D. L., Slack, R. S., Dickstein, R. J., Parikh, S., Chiong, E., Siefker-Radtke, A. O., Guo, C. C., Czerniak, B. A., McConkey, D. J., Shah, J. B., Pisters, L. L., Grossman, H. B., Dinney, C. P., Kamat, A. M. 2017; 119 (5): 684-691

Abstract

To analyse survival in patients with clinically localised, surgically resectable micropapillary bladder cancer (MPBC) undergoing radical cystectomy (RC) with and without neoadjuvant chemotherapy (NAC) and develop risk strata based on outcome data.A review of our database identified 103 patients with surgically resectable (=cT4acN0 cM0) MPBC who underwent RC. Survival estimates were calculated using Kaplan-Meier method and compared using log-rank tests. Classification and regression tree (CART) analysis was performed to identify risk groups for survival.For the entire cohort, estimated 5-year overall survival and disease-specific survival (DSS) rates were 52% and 58%, respectively. CART analysis identified three risk subgroups: low-risk: cT1, no hydronephrosis; high-risk: =cT2, no hydronephrosis; and highest-risk: cTany with tumour-associated hydronephrosis. The 5-year DSS for the low-, high-, and highest-risk groups were 92%, 51%, and 17%, respectively (P < 0.001). Patients down-staged at RC

View details for DOI 10.1111/bju.13689

View details for PubMedID 27753185